Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03781167) enrolled 244 people in total — 131 in a lower-dose group and 113 in a higher-dose group — who received a medication called ABBV-951. The trial was primarily measuring safety-related information: how many participants experienced unwanted medical events (called adverse events), whether certain specific types of reactions occurred, how the skin reacted at the site where the medication was delivered under the skin, and whether certain blood measurements changed over time. The reported data shows that, across all 244 participants combined, 230 out of 244 experienced at least one adverse event of any kind during the study, and 63 out of 244 experienced a serious adverse event (meaning an event considered potentially life-threatening, requiring hospitalisation, or similarly significant). When looking at a pre-specified list of particular events of interest — such as reactions at the infusion site, hallucinations, falls, nerve problems, weight loss, or drowsiness — the reported data shows 86 out of 244 participants had an infusion site infection or reaction, 200 out of 244 had some form of infusion site reaction overall, 61 out of 244 experienced falls, and 74 out of 244 experienced somnolence (drowsiness). Regarding skin reactions at the delivery site, 25 out of 244 participants recorded a score at or above the threshold defined as a notable skin reaction. For blood measurements, the reported data shows small decreases from the start to the end of the study in haemoglobin levels, red blood cell counts, and the proportion of red blood cells in the blood across both dose groups, though specific figures were not reported for all individual time points. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 41984314) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Parkinson's Disease Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with Parkinson's Disease that responds to a medication called levodopa
- Your doctor feels your Parkinson's symptoms are not well enough controlled by your current treatment
- You experience noticeable periods when your medication is working well ("On" time) and periods when it is not working as well ("Off" time)
- You have at least 2.5 hours per day when your Parkinson's symptoms are not well controlled ("Off" time)
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have problems with memory or thinking that would make it difficult to safely use the drug delivery device, fill in daily diaries, or follow the study instructions
- The doctor running the trial does not think you would be a suitable candidate for the study medication (ABBV-951) for any reason (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: ABBVIE INC., AbbVie
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 5 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Number of Participants With Adverse Events; Number of Participants With Adverse Events of Special Interest; Number of Participants With Numeric Grade Equal to or Higher Than 5 and With Letter Grade Equal to or Higher Than D on the Infusion Site Evaluation Scale; Hematocrit (Hematology): Change From Baseline to End of Study; Hemoglobin (Hematology): Change From Baseline to End of Study; Red Blood Cell (RBC) Count (Hematology): Change From Baseline to End of Study; White Blood Cell (WBC) Count (Hematology): Change From Baseline to End of Study; Neutrophils (Hematology): Change From Baseline to E...
Other options
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.